Improvement in social functioning in kidney transplant patients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®): Three case studies

Drugs

Volumn 66, Issue SUPPL. 2, 2006, Pages 15-17

  Shah, Tariq ^a  

^a National Institute of Transplantation Los Angeles   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TSUKUBAENOLIDE;

ABDOMINAL PAIN; ADULT; ANAMNESIS; ANOREXIA; ARTICLE; BLOATING; CASE REPORT; DIARRHEA; DRUG SUBSTITUTION; DYSPEPSIA; ENTERIC COATED TABLET; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; NAUSEA; SATIETY; SIDE EFFECT; SOCIAL INTERACTION; VOMITING;

EID: 33751527410     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666010-00002     Document Type: Article

References (9)

1. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118: 622-9
2. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81: 1290-7
3. Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005; 19: 779-84
4. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200-5
5. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381-6
6. Hardinger K, Brennan DC, Lowell J, et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004; 17: 609-16
7. Schnitzler MA, Hardinger KL, Burroughs TE, et al. Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant. Am J Transplant 2005; 5(S11): 242
8. Salvadori M, Holzer H, de Mattos AM, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-6
9. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237-43